Peptide Coacervates for pH-Responsive Insulin Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current delivery systems for pharmaceutical agents, particularly insulin, lack efficient and controllable methods for targeted delivery and glucose-responsive release, which is crucial for managing diabetes and other conditions.
Innovation Solution
Peptide coacervates formed from histidine-rich proteins, such as those derived from squid beak proteins, are used to encapsulate active agents like insulin, enabling efficient delivery and controlled release through pH-responsive mechanisms, including glucose-induced acidification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional delivery systems are used for insulin, then the insulin can be delivered to patients, but the delivery lacks efficiency and controllable release mechanisms
Solution Approach 1:
The peptide coacervate system utilizes pH as a controllable parameter to regulate insulin release. The histidine-rich peptides undergo coacervation at physiological pH (7.4) to form encapsulating droplets, and dissolve at acidic pH (below 6.5) to release insulin. This parameter-based control mechanism enables efficient and controllable delivery without complex mechanical or electronic components.
2Reliability
If peptide coacervates are used for encapsulation, then encapsulation efficiency is high, but the system requires specific pH conditions for formation and release
Solution Approach 1:
The peptide coacervate system is self-regulating through the intrinsic pH-responsive properties of histidine-rich peptides. The peptides automatically undergo coacervation at physiological pH to encapsulate insulin with high efficiency, and automatically dissolve at acidic pH to release the drug. This self-service mechanism eliminates the need for external control systems while maintaining high adaptability to physiological conditions.
3Reliability
If frequent insulin injections are administered, then glucose levels can be managed, but patient compliance and quality of life are reduced
Solution Approach 1:
The peptide coacervate system incorporates a feedback mechanism where the pH of the local environment controls insulin release. In physiological conditions (pH 7.4), the coacervates remain stable and encapsulated. When glucose levels rise and create acidic conditions (pH below 6.5), the coacervates dissolve and release insulin, which then normalizes glucose levels and returns pH to baseline. This automatic feedback loop reduces the need for frequent injections and improves patient compliance while maintaining reliable glucose management.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide coacervates provide high encapsulation efficiency and controlled release of insulin in response to glucose levels, potentially reducing the frequency of insulin injections and improving glucose management in diabetic patients.
Implementation Method 1
DgHBPs exhibit self-coacervation ability, a liquid-liquid phase separation (LLPS) process resulting in the formation of highly concentrated protein microdroplets
Implementation Method 2
The peptide coacervates provide high encapsulation efficiency and controlled release of insulin in response to glucose levels, potentially reducing the frequency of insulin injections
Data Source
AI summary
Described herein is a composition for delivery of an active agent. The composition includes a peptide coacervate, wherein the peptide coacervate includes one or more peptides derived from histidine-rich proteins, and an active agent encapsulated in the peptide coacervate. Further provided are a method for encapsulation of an active agent in a peptide coacervate, a method for delivery of an active agent, and a method for treating or diagnosing a condition or disease in a subject in need thereof.